hat
Pousantaj nan sispansyon sevè akòz evènman negatif yo te pousantaj 2.5, pousan 5.0 ak pousan 2.5 pou miligrams cetilistat 120, miligram 80 ak miligram 40 respektivman. Sa a se an konparezon pou pousantaj 11.6 pou Orlistat ak 6.4 pousan pou plasebo. Rezon prensipal ki pou kout tèm itilizasyon klinik nan Orlistat se efè segondè dwòg la efè gastwoentestinal.
eng
Rates of hasty discontinuation due to adverse events were 2.5 percent, 5.0 percent and 2.5 percent for cetilistat 120 milligrams, 80 milligrams and 40 milligrams respectively. This is in comparison to 11.6 percent for Orlistat and 6.4 percent for placebo. The main reason for short-term clinical utilization of Orlistat is the drug’s troublesome gastrointestinal side effects.